Arthroscopic glenoid resurfacing as a surgical treatment for glenohumeral arthritis in the young patient: midterm results.
OBJECTIVE
This study investigates the hypothesis that arthroscopic biologic glenoid resurfacing without humeral head replacement will provide results similar to humeral hemiarthroplasty in patients aged under 60 years.


METHODS
Twenty-three consecutive patients aged 15 to 58 years (mean, 32 years) with severe glenohumeral arthritis were prospectively treated with arthroscopic resurfacing of the glenoid with a biologic patch (Restore; DePuy Orthopaedics, Warsaw, IN). Three patients left the study, leaving twenty patients to complete the study. Data collected preoperatively and postoperatively included active and passive range of motion and American Shoulder and Elbow Surgeons (ASES); Constant-Murley; Rowe; University of California, Los Angeles (UCLA); Short Form 12 (SF-12); and visual analog scale (VAS) pain scores. All patients had preoperative and postoperative imaging, either computed tomography scan (n = 2) or magnetic resonance imaging (n = 18), and were re-examined 3 to 6 years after surgery.


RESULTS
At last follow-up, 15 patients (75%) remained satisfied. Five patients had proceeded to have surface replacement arthroplasty, but four of five said that they would undergo the arthroscopic procedure again. Active and passive range of motion improved in flexion (80 degrees to 150 degrees ), abduction (60 degrees to 120 degrees ), external rotation with the arm at the side (10 degrees to 30 degrees ), external rotation in abduction (30 degrees to 70 degrees ), and internal rotation (10 degrees to 50 degrees ). Each rating scale used showed statistically significant (P < .05) improvement from preoperatively to postoperatively: VAS, from 8 to 2; ASES, from 22 (out of 100) to 78; UCLA, from 15 (out of 35) to 29; Rowe, from 55 (out of 100) to 81; and Constant-Murley, from 26 to 79. Six of eight parameters on the SF-12 also showed statistically significant improvements.


CONCLUSIONS
Glenoid resurfacing with the Restore patch provided statistically significant improvements for young patients with severe glenohumeral arthritis as measured by the VAS, ASES, UCLA, Rowe, Constant-Murley, and SF-12 scores at 3 to 6 years of follow-up.


METHODS
Level IV, prospective case series investigating the effect of arthroscopic resurfacing rather than shoulder humeral hemiarthroplasty for grade IV arthritis of the glenohumeral joint.
Savoie
Felix H
FH
Department of Orthopaedic Surgery, Tulane University, New Orleans, LA70112, USA. FSavoie@tulane.edu
Brislin
Kenneth J
KJ
Argo
David
D
D000293:Adolescent; D000305:Adrenal Cortex Hormones / Q000008:administration & dosage / Q000627:therapeutic use; D000328:Adult; D000818:Animals; D001168:Arthritis / Q000000981:diagnostic imaging / Q000188:drug therapy / Q000601:surgery* / Q000628:therapy; D001182:Arthroscopy / Q000379:methods*; D001705:Bioprosthesis; D002809:Chondroitin Sulfates / Q000627:therapeutic use; D003131:Combined Modality Therapy; D005260:Female; D005500:Follow-Up Studies; D005944:Glucosamine / Q000627:therapeutic use; D006801:Humans; D007270:Injections, Intra-Articular; D054327:Lubricants / Q000008:administration & dosage / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D026741:Physical Therapy Modalities; D011446:Prospective Studies; D011859:Radiography; D016059:Range of Motion, Articular; D020127:Recovery of Function; D012540:Scapula / Q000000981:diagnostic imaging / Q000601:surgery*; D012785:Shoulder Joint / Q000000981:diagnostic imaging / Q000601:surgery*; D016896:Treatment Outcome; D055815:Young Adult
D000305:Adrenal Cortex Hormones; D054327:Lubricants; D002809:Chondroitin Sulfates; D005944:Glucosamine